細胞凋亡，蛋白激酶抑制劑，抗體:藥物開發策略分析 是由出版商BioSeeker Group AB在2012年05月所出版的。
這份英文市場調查報告書包含6501 Pages 價格從美金5175起跳。
本報告以癌症治療藥開發策略上細胞凋亡及蛋白激酶抑制劑的機制、目標、影響領域及抗體的化合物領域為焦點，彙整各種的劑目標策略，化合物策略競爭基準，開發平台開發平台及最佳投資組合計劃等資料，為您概述為以下內容。
第1章 細胞凋亡
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:細胞凋亡治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:細胞凋亡藥物的各類型化合物的競爭基準
- 細胞凋亡的癌適應症症狀選擇
- 最佳投資組合計劃:細胞凋亡開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第2章 蛋白激酶抑制劑
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:癌症的蛋白激酶抑制劑治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:各化合物策略競爭基準
- 蛋白激酶抑制劑的癌症適應
- 最佳投資組合計劃:蛋白激酶抑制劑癌症治療藥開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第3章 抗體
- 本報告的範圍
- 為達成最高治療效果及投資報酬率治療目標
- 新藥的上市:癌症的抗體治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 抗體治療藥物的癌適應症症狀的選擇
- 最佳投資組合計劃:癌症的抗體治療開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
Abstract
Product Description
This triple analysis focuses on cancer drug development strategies by the two
mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and
by the compound strategy of Antibodies. Each of these three individual parts
is evaluated according to standardized criteria in a five pillar pipeline drug
assessment methodology to compare drug development strategies in oncology.
This makes it easy to find and compare analysis not only within one single
cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Apoptosis
The apoptosis report part comprises defined and up to date development
strategies for 171 apoptotic drugs in oncology (519 projects) within the
portfolio of 125 investigators, from Ceased to Pre-registration. This report
part extensively analyses 146 identified targets of apoptotic drugs, organized
into 120 drug target strategies, and assesses them in 53 different cancer
indications.
Part II: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development
strategies for 409 protein kinase drugs (990 projects) within the portfolio of
160 investigators, from Ceased to Marketed. This report part extensively
analyses 133 identified targets of protein kinase drugs, organized into 200
drug target strategies, and assesses them in 57 different cancer indications.
Part III: Antibodies
The cancer antibody drug report part comprises defined and up to date
development strategies for 531 antibody drugs in oncology within the portfolio
of 196 companies world-wide, from Ceased to Marketed. The report extensively
analyses their 255 identified drug targets, organized into 266 drug target
strategies, and assesses them in 75 cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Apoptosis
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (146 Drug Targets)
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic
Pipeline? (120 Drug Target Strategies and 171 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs
in Oncology by Compound Type (7 Different Compound Strategies)
- 9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer
Indications)
- 10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer
Therapeutic Pipeline by Investigator (125 Investigators)
- 12 Drug Index
- 13 Company Index
Part II: Protein Kinase Inhibitors
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (133 Drug Targets)
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Protein Kinase
Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase
Drugs in Oncology by Compound Type (7 Compound Strategies)
- 9 Selecting Cancer Indications for Protein Kinase Therapeutics (57
Different Cancer Indications)
- 10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer
Therapeutic Pipeline by Investigator (160 Investigators)
- 12 Drug Index
- 13 Company Index
Part III: Antibodies
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the
Highest Therapeutic Outcome and Return on Investment (255 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug
Targets Strategies and 531 Antibody Drugs)
- 8 Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications)
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the
Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531
Antibody Drugs)
- 10 Disclaimer
- 11 Drug Index
- 12 Company Index
Featured Compnaies
This Report Includes the Following Companies:
- 4SC
- A&G Pharmaceutical
- Abbott
- Abiogen
- Ablynx
- Abraxis BioScience
- AC Immune
- Acceleron Pharma
- Access
- Actinium Pharmaceuticals
- Active Biotech
- Adherex
- Advanced Life Sciences
- Advenchen
- AEgera
- AEterna Zentaris
- Affibody
- Affimed Therapeutics
- Affitech
- AGY Therapeutics
- Aida Pharmaceuticals
- Alder Biopharmaceuticals
- Alethia Biotherapeutics
- Alexion
- Alfacell
- Algeta
- AlphaVax
- ALSP
- Altor BioScience
- Ambit Biosciences
- Ambrilia Biopharma
- Amgen
- Amorfix Life Sciences
- Amphora
- Anavex Life Sciences
- Antisoma
- Aphios
- ApopLogic Pharmaceuticals
- Apricus Biosciences
- Apthera
- Arana Therapeutics
- Arca biopharma
- arGEN-X
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Astellas
- Astex Therapeutics
- AstraZeneca
- Attenuon
- Avaxia
- AVEO
- Bayer
- Benitec
- Berkeley Lab
- BioAxone
- Biocon
- Biogen Idec
- BioInvent
- Biolex
- BioLineRx
- Bionovo
- Biosceptre
- Biotecnol
- Biotest
- BioVex
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Callisto Pharmaceuticals
- CanBas
- Cancer Innovations
- Cancer Research Technology
- Celgene
- Cell Therapeutics
- Celldex Therapeutics
- Celltrion
- Celtic Pharma
- Center of Molecular Immunology
- Cephalon
- CG Therapeutics
- ChemoCentryx
- Circadian Technologies
- CompleGen
- Coronado Biosciences
- Critical Outcome Technologies
- CSL
- CuraGen
- CureTech
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- CytImmune Sciences
- Cytochroma
- Daewoong
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Deciphera Pharmaceuticals
- Dendreon
- DeveloGen
- DiaMedica
- Dompe
- Dr Reddy' s
- Dyax
- Eisai
- Elan
- Elara Pharmaceuticals
- Eleos
- Eli Lilly
- Emergent BioSolutions
- Enkam Pharmaceuticals
- EntreMed
- Enzon
- EpiCept
- Epitomics
- EUSA Pharma
- Exelixis
- Faron Pharmaceuticals
- Favrille
- Femta Pharmaceuticals
- FibroGen
- Five Prime Therapeutics
- Fusion Antibodies
- Galapagos
- Galaxy Biotech
- GammaCan
- Ganymed Pharmaceuticals
- Gene Techno Science
- Genencor
- Genentech
- Generex
- Genmab
- Genomic Systems
- GenPat77
- Genta
- Genzyme
- Geron
- Gilead Sciences
- GlaxoSmithKline
- Gliknik
- GlycoGenesys
- Glycotope
- Green Cross
- Hanmi
- Hawthorn Pharmaceuticals
- Hoffmann-La Roche
- Human Genome Sciences
- Idera Pharmaceuticals
- IDM Pharma
- ImClone Systems
- IMED
- Immune Pharmaceuticals
- ImmunoCellular Therapeutics
- ImmunoFrontier
- ImmunoGen
- Immunomedics
- Immutep
- Incyte Corporation
- Infinity Pharmaceuticals
- Innate Pharma
- InNexus Biotechnology
- Inovio
- Insmed
- Intracel
- Intradigm
- Introgen Therapeutics
- ISA Pharmaceuticals
- Isis Pharmaceuticals
- ISU ABXIS
- Johnson & Johnson
- KAI Pharmaceuticals
- Kaketsuken
- KaloBios
- Kalypsys
- Kiadis
- Kirin Pharma
- Kissei
- Kyowa Hakko Kirin
- Kyto Biopharma
- LFB Biotechnologies
- LG Life Sciences
- Locus Pharmaceuticals
- Lorus Therapeutics
- MacroGenics
- MAT Biopharma
- MaxoCore Pharmaceuticals
- Medarex
- MediGene
- MedImmune
- Medisyn Technologies
- Menarini
- Merck & Co
- Merck KGaA
- Merrimack
- MethylGene
- Micromet
- Mitsubishi Tanabe Pharma
- Mycenax
- NeoPharm
- Neovacs
- Nerviano Medical Sciences
- Neuren
- NicOx
- Nidus Laboratories
- NIH
- Nippon Shinyaku
- NKT Therapeutics
- Non-industrial source
- Northwest Biotherapeutics
- Novacea
- Novartis
- Novelix
- Novogen
- Oncalis
- OncoMed
- Onconova
- OncoTherapy Science
- Oncothyreon
- Onyvax
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Paladin Labs
- Panacea
- PanaGin
- PanGenetics
- Patrys
- Pepscan Therapeutics
- Peregrine Pharmaceuticals
- Perseus Proteomics
- Pfizer
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharmexa
- Pharminox
- Philogen
- Pierre Fabre
- Piramal
- Plexxikon
- Prima Biomed
- ProCell Therapeutics
- Prochon Biotech
- Progenics Pharmaceuticals
- Ramot
- Reata Pharmaceuticals
- Recepta biopharma
- Receptor BioLogix
- Regeneron
- Regulon
- Rexahn
- Rigel
- Sanofi-Aventis
- Santaris Pharma
- Sareum
- SBI Biotech
- SBIO
- Scancell
- Schering-Plough
- Seattle Genetics
- Semafore Pharmaceuticals
- Shenogen
- Sigma-Tau
- Silence Therapeutics
- SRI International
- Stainwei Biotech
- Sunol Molecular
- SuperGen
- SuppreMol
- Supratek Pharma
- Switch Pharma
- Symbiotec
- Symphogen
- Synageva BioPharma
- SynerGene Therapeutics
- Takeda
- Targa Therapeutics
- TargeGen
- Taxolog
- TeGenero
- Tekmira Pharmaceuticals
- Telik
- Teva
- Thallion Pharmaceuticals
- Therapure Biopharma
- Theryte
- ThromboGenics
- Tigris Pharmaceuticals
- Titan Pharmaceuticals
- Tolerx
- ToolGen
- TopoTarget
- Tracon Pharmaceuticals
- Transgene
- Trillium Therapeutics
- Trion Pharma
- UCB
- United Therapeutics
- Vaccinex
- Wakunaga
- Vascular Biogenics
- VasGene Therapeutics
- Vertex Pharmaceuticals
- Wilex
- VioQuest
- Viragen
- Viralytics
- ViroMed
- ViroTarg
- Viventia Biotech
- Wyeth
- XBiotech
- Xencor
- Xerion
- Xoma
- Y' s Therapeutics
- YM BioSciences
- Zenotech
- ZymoGenetics
featured Drugs
A Shortlist of Drugs Included are:
- 131I-tositumomab
- 2-methoxyestradiol
- abagovomab
- ABT-263
- AEG-35156
- aflibercept
- afutuzumab
- alemtuzumab
- alvocidib
- AMG-386
- Apomab
- ARQ-197
- AS-1411
- atiprimod dimaleate
- ATN-224
- axitinib
- belinostat
- bevacizumab
- BIBW-2992
- brentuximab vedotin
- brivanib alaninate
- BZL-101
- canfosfamide hydrochloride
- catumaxomab
- CBLC-102
- cediranib
- cenersen
- cetuximab
- cintredekin besudotox
- combretastatin A-4 prodrug
- conatumumab
- CS-1008
- dasatinib
- deforolimus
- denosumab
- dulanermin
- E-75
- enzastaurin hydrochloride
- erlotinib
- everolimus
- farletuzumab
- galiximab
- GCS-100LE
- gefitinib
- gemtuzumab ozogamicin
- girentuximab
- GRN-163L
- HE-3235
- ibritumomab tiuxetan
- idronoxil
- imatinib mesilate
- indisulam
- INGN-241
- INGN-401
- inotuzumab ozogamicin
- ipilimumab
- ISIS-23722
- kahalalide F
- lapatinib ditosylate
- lestaurtinib
- lonaprisan
- lumiliximab
- mapatumumab
- MGCD-0103
- midostaurin
- MKC-1
- motesanib diphosphate
- motexafin gadolinium
- naptumomab estafenatox
- necitumumab
- nilotinib
- nimotuzumab
- obinutuzumab
- oblimersen sodium
- ofatumumab
- oregovomab
- panitumumab
- panobinostat
- PARP inhibitors
- PAT-SC1
- patupilone
- pazopanib hydrochloride
- PCI-24781
- pertuzumab
- plitidepsin
- quarfloxacin
- ramucirumab
- Reditux
- retaspimycin
- Rh-Apo2L
- rituximab
- sagopilone
- seliciclib
- sorafenib tosylate
- sunitinib malate
- tanespimycin
- temsirolimus
- tigapotide triflutate
- TLN-232
- trastuzumab
- triciribine
- TRU-016
- vandetanib
- voreloxin
- VX-944
- XL-184
- XL-647
- zalutumumab
- zanolimumab
